Sana Biotechnology, Inc. (SANA): Price and Financial Metrics


Sana Biotechnology, Inc. (SANA): $4.93

0.40 (+8.83%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SANA to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

SANA Stock Price Chart Interactive Chart >

Price chart for SANA

SANA Price/Volume Stats

Current price $4.93 52-week high $26.60
Prev. close $4.53 52-week low $4.15
Day low $4.40 Volume 1,650,200
Day high $5.09 Avg. volume 1,362,689
50-day MA $7.02 Dividend yield N/A
200-day MA $14.00 Market Cap 935.06M

Sana Biotechnology, Inc. (SANA) Company Bio


Sana Biotechnology, Inc. operates as a biotechnology company. The Company focuses on creating and delivering engineered cells as medicine for patients. Sana Biotechnology replaces damaged cells and tissues and treats broad array of diseases.


SANA Latest News Stream


Event/Time News Detail
Loading, please wait...

SANA Latest Social Stream


Loading social stream, please wait...

View Full SANA Social Stream

Latest SANA News From Around the Web

Below are the latest news stories about Sana Biotechnology Inc that investors may wish to consider to help them evaluate SANA as an investment opportunity.

Biotech IPOs Have Slowed to a Snail's Pace

Decline tied to falling stock prices of newly minted companies

Yahoo | February 17, 2022

INVAIO SCIENCES STRENGTHENS ITS BOARD OF DIRECTORS WITH THE APPOINTMENT OF HUGH GRANT

Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agricultural, sustainability, and environmental challenges, today announced the appointment of Hugh Grant to its Board of Directors.

Yahoo | February 15, 2022

Sana Biotechnology: Exciting Preclinical Science

No summary available.

Seeking Alpha | February 12, 2022

3 Biotechs That Will Soar Regardless of COVID-19

In the healthcare markets, much time and energy have been focused on COVID-19. But there are some amazing opportunities outside the COVID space.

Yahoo | January 27, 2022

Sana Biotechnology Inks Two Licensing Pacts For Targets Against Hematological Malignancies

Sana Biotechnology Inc (NASDAQ: SANA) has obtained non-exclusive commercial rights to a clinically validated fully-human BCMA CAR construct from IASO Biotherapeutics and Innovent Biologics. The constructs can be used in certain in vivo gene therapy and ex vivo hypoimmune cell therapy applications. IASO Bio and Innovent will receive an upfront payment and are entitled to receive up to approximately $204 million in potential development and regulatory milestone payments across up to six products,

Yahoo | January 11, 2022

Read More 'SANA' Stories Here

SANA Price Returns

1-mo -34.00%
3-mo -23.92%
6-mo -72.26%
1-year -76.49%
3-year N/A
5-year N/A
YTD -68.15%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6829 seconds.